NBIX Neurocrine Biosciences, Inc. - Common Stock
$155,80
Kurs · Aug 19, 2026
Fundamentaldaten per Jul 31, 2026
52W-Spanne
$123–$186
52% of range
Analystenbewertung
BUY
36 analysts
Kursziel
$212
+36% upside
P/E (TTM)
33.4
ROE
16.1%
Nettogewinnmarge
16.7%
Über Neurocrine Biosciences, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
Mehr lesen
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
History
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.
In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.
In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.
In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.
In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.
In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.
In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.
Product pipeline
Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids
Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease
NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist
NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
NBIX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$155.79
Marktkapitalisierung
$15.60B
P/E (TTM)
33.4
EPS (TTM)
$4.67
Umsatz (TTM)
$2.86B
Dividendenrendite
—
ROE
16.1%
Verschuldungsgrad
—
52W-Spanne
$123 – $186
NBIX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$2.86B
2016-12-31
→
2025-12-31
EPS
$4.67
2016-12-31
→
2025-12-31
Freier Cashflow
$749M
2016-12-31
→
2025-12-31
Margen
16.7%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
NBIX
Peer-Median
P/E (TTM)
33.4
16.9
P/S (TTM) (K/V (TTM))
5.5
9.6
P/B (K/B)
4.8
7.7
Price / FCF (Kurs / FCF)
20.8
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
NBIX
Peer-Median
Operating Margin (Betriebsgewinnmarge)
21.6%
—
Net Profit Margin (Nettogewinnmarge)
16.7%
-36.9%
ROA
11.5%
-21.8%
ROE
16.1%
-47.3%
ROIC
12.9%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
NBIX
Peer-Median
Current Ratio (Liquiditätsgrad)
3.4
3.5
Quick Ratio
1.9
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
NBIX
Peer-Median
Revenue YoY (Umsatz YoY)
21.4%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
24.3%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
22.3%
—
EPS YoY (EPS VjV)
41.9%
—
Net Income YoY (Nettogewinn YoY)
40.2%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
NBIX
Peer-Median
NBIX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
36 Analysten
- Starker Kauf 14 38,9%
- Kauf 17 47,2%
- Halten 5 13,9%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
27 Analysten · 2026-08-15
Median
$215.00
← Unter allen Zielen
$155.79
Tief
$165.00
Hoch
$249.00
Median-Ziel
$215.00
+38,0%
Mittelwert-Ziel
$211.57
+35,8%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.24%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $1.39 | $1.37 | 0.02% |
| 31. März 2026 | $1.91 | $1.20 | 0.71% |
| 31. Dezember 2025 | $1.91 | $1.20 | 0.71% |
| 30. September 2025 | $2.04 | $1.62 | 0.42% |
| 30. Juni 2025 | $1.06 | $0.99 | 0.07% |
| 31. März 2025 | $0.08 | $0.56 | -0.48% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Cost of Revenue | $52M | $34M | $40M | $23M | $14M | $10M | · | $5M | $1M | $0 | $0 | · | |
| R&D Expense | · | · | · | · | · | · | · | $161M | $122M | $94M | $81M | $46M | |
| SG&A Expense | $1.16B | $1.01B | $888M | $753M | $583M | $433M | $354M | $249M | $170M | $68M | $32M | $18M | |
| Operating Expenses | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B | $883M | $716M | $414M | $293M | $162M | $114M | $64M | |
| Operating Income | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | $-94M | $-64M | |
| Interest Expense | · | · | $5M | $7M | $26M | $33M | $32M | $30M | $20M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $3M | $2M | $629.0K | |
| Other Non-op | $86M | $-84M | $81M | $-35M | $-1M | $-56M | $-26M | $-15M | $-11M | $6M | $20.0K | $18.0K | |
| Pretax Income | $705M | $486M | $332M | $214M | $101M | $107M | $46M | $22M | $-143M | $-141M | · | · | |
| Income Tax | $227M | $145M | $82M | $59M | $12M | $-301M | $10M | $700.0K | $0 | $0 | $0 | $0 | |
| Net Income | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| Shares (Basic) | 99,500,000 | 100,400,000 | 97,700,000 | 95,800,000 | 94,600,000 | 93,100,000 | 91,600,000 | 90,200,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| Shares (Diluted) | 102,500,000 | 103,700,000 | 101,000,000 | 98,900,000 | 97,900,000 | 97,800,000 | 95,700,000 | 95,400,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| EBITDA | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | · | $-64M |
Bilanz 28
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713M | $233M | $251M | $263M | $341M | $187M | $112M | $142M | $255M | $83M | $74M | $31M | |
| Short-term Investments | · | · | · | · | $370M | $614M | $558M | $509M | $261M | $224M | $305M | $163M | |
| Receivables | $687M | $479M | $439M | $350M | $186M | $157M | $127M | $57M | $31M | $0 | · | · | |
| Inventory | $69M | $57M | $38M | $35M | $30M | $28M | $17M | $11M | $1M | $0 | · | · | |
| Prepaid Expense | $171M | $48M | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $116M | $64M | $98M | $79M | $46M | $30M | $17M | $19M | $7M | $3M | $5M | $4M | |
| Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $973M | $1.02B | $831M | $738M | $555M | $310M | $384M | $198M | |
| PP&E (Net) | $90M | $83M | $71M | $59M | $59M | $45M | $42M | $34M | $11M | $6M | $3M | $3M | |
| PP&E (Gross) | $208M | $189M | $154M | $125M | $110M | $86M | $76M | $62M | $38M | $32M | $30M | $31M | |
| Accum. Depreciation | $118M | $106M | $83M | $66M | $52M | $42M | $34M | $28M | $28M | $26M | $27M | $29M | |
| Goodwill | $6M | $6M | $6M | $5M | $0 | · | · | · | · | · | · | · | |
| Intangibles | $5M | $36M | $36M | $37M | $0 | · | · | · | · | · | · | · | |
| Other Non-current Assets | $49M | $52M | $50M | $25M | $4M | $6M | $0 | · | · | · | · | · | |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Accounts Payable | $674M | $462M | $449M | $348M | $226M | $169M | $141M | $86M | $6M | $5M | $3M | $246.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $21M | $19M | $12M | |
| Current Liabilities | $743M | $508M | $655M | $538M | $246M | $186M | $565M | $88M | $54M | $30M | $26M | $16M | |
| Capital Leases | $415M | $455M | $258M | $94M | $105M | $94M | $87M | $0 | · | · | · | · | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $220M | $166M | $106M | $30M | $12M | $10M | $17M | $36M | $0 | $113.0K | $221.0K | $260.0K | |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $661M | $698M | $608M | $669M | $512M | $445M | $50M | $50M | $34M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $91.0K | $89.0K | $87.0K | $86.0K | $76.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $1.04B | |
| Retained Earnings | $448M | $29M | $-157M | $-407M | $-636M | $-725M | $-1.13B | $-1.18B | $-1.20B | $-1.06B | $-915M | $-826M | |
| AOCI | $13M | $6M | $7M | $-8M | $-2M | $2M | $1M | $-2M | $-2M | $-318.0K | $-977.0K | $-277.0K | |
| Stockholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $637M | $481M | $372M | $315M | $424M | $209M | |
| Liabilities + Equity | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Shares Outstanding | 100,100,000 | 99,400,000 | 98,700,000 | 96,500,000 | 94,900,000 | 93,500,000 | 92,300,000 | 90,797,000 | 88,793,903 | 86,883,300 | 86,262,594 | 76,465,942 |
Cashflow 15
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $4M | $2M | $1M | $1M | $827.0K | |
| Stock-based Comp | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M | $28M | $10M | |
| Deferred Tax | $164M | $-123M | $-61M | $22M | $6M | $-311M | $0 | $0 | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $4M | $500.0K | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $783M | $595M | $390M | $339M | $256M | $228M | $147M | $101M | $-94M | $-106M | $-38M | $-47M | |
| CapEx | $34M | $38M | $28M | $16M | $23M | $11M | $15M | $25M | $7M | $4M | $2M | $2M | |
| Investing Cash Flow | $-264M | $-127M | $-467M | $-177M | $-130M | $4M | $-211M | $-243M | $-251M | $113M | · | · | |
| Stock Issued | $129M | $122M | $65M | $45M | $28M | $29M | $32M | $30M | $14M | $2M | $277M | $139M | |
| Stock Repurchased | $168M | $300M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-38M | $-178M | $65M | $45M | $28M | $29M | $27M | $30M | $14M | $2M | · | $139M | |
| Financing Cash Flow | $-38M | $-487M | $65M | $-234M | $27M | $-158M | $32M | $30M | $517M | $2M | · | · | |
| Net Change in Cash | $480M | $-18M | $-12M | $-73M | $154M | $75M | $-32M | $-112M | $171M | $9M | $43M | $-14M | |
| Taxes Paid | $81M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $749M | $557M | $362M | $323M | $233M | $218M | $137M | $77M | $-101M | $-110M | · | $-49M | |
| Levered FCF | · | · | $358M | $318M | $210M | $92M | $112M | $47M | · | · | · | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | · | · | |
| Pretax Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | 10.2% | 5.9% | 4.8% | · | · | · | · | |
| EBITDA Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| ROA | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% | · | -30.4% | |
| ROE | 16.1% | 12.9% | 11.8% | 9.5% | 6.6% | 42.2% | 6.1% | 4.5% | -41.5% | -38.2% | · | -36.8% | |
| ROIC | 12.9% | 15.5% | 8.5% | 10.5% | 6.6% | 55.2% | 9.0% | 7.4% | · | · | · | · |
Liquidität & Solvenz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 | 5.4 | 1.5 | 8.4 | 10.2 | 10.2 | · | 12.7 | |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 | 5.1 | 1.4 | 2.2 | 10.1 | 10.1 | · | 12.4 | |
| Interest Coverage | · | · | 54.5 | 35.1 | 4.0 | 5.0 | 2.3 | 1.2 | -6.7 | · | · | · |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.7 | 0.7 | 0.5 | 0.3 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.8 | 0.7 | 1.1 | 0.7 | · | · | · | 0.8 | · | · | · | · | |
| Receivables Turnover | 4.9 | 5.1 | 4.8 | 5.6 | 6.6 | 7.4 | 8.6 | 10.3 | 10.4 | · | · | · |
Wachstumsraten 9
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 24.3% | 27.6% | 21.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 22.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 41.9% | 33.2% | 58.3% | 69.6% | -77.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 44.1% | 52.9% | -16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 40.2% | 36.7% | 61.6% | 72.4% | -78.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 45.8% | 56.2% | -15.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 3.3% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Net Income TTM | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| Market Cap | $14.20B | $13.57B | $13.00B | $11.53B | $8.08B | $8.96B | $9.92B | $6.48B | $6.89B | $3.36B | · | $1.71B | |
| P/E | 30.4 | 41.5 | 53.3 | 76.6 | 92.6 | 23.0 | 275.6 | 324.6 | -47.9 | -23.7 | -53.9 | -27.6 | |
| P/S | 5.0 | 5.8 | 6.9 | 7.7 | 7.1 | 8.6 | 12.6 | 14.4 | 42.6 | 224.2 | · | · | |
| P/B | 4.4 | 5.2 | 5.8 | 6.7 | 5.9 | 8.0 | 15.6 | 13.5 | 18.5 | 10.7 | · | 8.2 | |
| P / Tangible Book | 4.4 | 5.3 | 5.9 | 6.9 | 5.9 | 8.0 | · | · | · | · | · | · | |
| P / Cash Flow | 18.1 | 22.8 | 33.4 | 34.0 | 31.5 | 39.2 | 65.2 | 64.0 | -73.0 | -31.7 | · | -36.2 | |
| P / FCF | 19.0 | 24.4 | 36.0 | 35.7 | 34.7 | 41.2 | 72.2 | 84.7 | -68.0 | -30.5 | · | -35.0 | |
| Earnings Yield | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.36% | 0.31% | -2.1% | -4.2% | -1.9% | -3.6% |
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959M | $814M | $806M | $795M | $688M | $573M | $628M | $622M | $590M | $515M | $515M | $499M | $453M | $420M | $412M | $388M | |
| Cost of Revenue | · | $14M | $18M | $14M | $11M | $9M | $9M | $8M | $9M | $8M | $8M | $11M | $12M | $8M | $8M | $6M | |
| SG&A Expense | $440M | $318M | $302M | $292M | $286M | $276M | $288M | $234M | $242M | $243M | $219M | $204M | $222M | $243M | $183M | $186M | |
| Operating Expenses | $808M | $621M | $595M | $556M | $542M | $549M | $486M | $438M | $445M | $416M | $365M | $358M | $379M | $535M | $309M | $300M | |
| Operating Income | $152M | $193M | $211M | $239M | $146M | $24M | $142M | $184M | $145M | $99M | $150M | $141M | $74M | $-114M | $103M | $88M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-op | $11M | $53M | $28M | $53M | $14M | $-9M | $21M | $6M | $-47M | $-65M | $48M | $-26M | $48M | $11M | $14M | $10M | |
| Pretax Income | $162M | $247M | $239M | $292M | $160M | $15M | $163M | $190M | $99M | $34M | $198M | $116M | $122M | $-103M | $118M | $98M | |
| Income Tax | $18M | $49M | $86M | $82M | $52M | $7M | $60M | $60M | $34M | $-9M | $50M | $32M | $26M | $-27M | $29M | $29M | |
| Net Income | $144M | $198M | $154M | $210M | $108M | $8M | $103M | $130M | $65M | $43M | $148M | $83M | $96M | $-77M | $89M | $68M | |
| EPS (Basic) | $1.43 | $1.97 | $1.53 | $2.11 | $1.09 | $0.08 | $1.05 | $1.28 | $0.64 | $0.43 | $1.52 | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | |
| EPS (Diluted) | $1.39 | $1.91 | $1.49 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 | $0.63 | $0.42 | $1.49 | $0.82 | $0.95 | $-0.79 | $0.91 | $0.69 | |
| Shares (Basic) | 101,000,000 | 100,500,000 | -198,600,000 | 99,400,000 | 99,000,000 | 99,700,000 | -201,300,000 | 101,100,000 | 100,800,000 | 99,800,000 | -194,900,000 | 97,900,000 | 97,600,000 | 97,100,000 | -190,900,000 | 95,800,000 | |
| Shares (Diluted) | 104,200,000 | 103,400,000 | -203,500,000 | 102,500,000 | 101,000,000 | 102,500,000 | -208,100,000 | 104,300,000 | 103,900,000 | 103,600,000 | -197,400,000 | 101,100,000 | 100,200,000 | 97,100,000 | -193,300,000 | 99,000,000 | |
| EBITDA | $152M | $193M | · | $239M | $146M | $24M | · | $184M | $145M | $99M | · | $141M | $74M | $-114M | · | $88M |
Bilanz 25
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $332M | $266M | $713M | $340M | $264M | $194M | $233M | $349M | $140M | $396M | · | $294M | $160M | $104M | · | $212M | |
| Receivables | $887M | $768M | $687M | $728M | $596M | $516M | $479M | $481M | $468M | $451M | · | $418M | $388M | $392M | · | $301M | |
| Inventory | $104M | $64M | $69M | $69M | $57M | $59M | $57M | $46M | $42M | $37M | · | $29M | $32M | $33M | · | $37M | |
| Prepaid Expense | $217M | $225M | $171M | $178M | · | · | $48M | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $39M | $62M | $116M | $68M | $121M | $119M | $64M | $122M | $120M | $100M | · | $108M | $101M | $113M | · | $68M | |
| Current Assets | $1.64B | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B | $1.80B | · | $1.65B | $1.50B | $1.43B | · | $1.21B | |
| PP&E (Net) | $90M | $91M | $90M | $97M | $92M | $87M | $83M | $80M | $80M | $75M | · | $69M | $66M | $63M | · | $61M | |
| PP&E (Gross) | · | · | $208M | · | · | · | $189M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $118M | · | · | · | $106M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $501M | · | · | · | · | · | · | $6M | $6M | $6M | · | $6M | $6M | $6M | $5M | · | |
| Intangibles | $2.23B | · | · | $36M | $37M | $36M | · | $34M | $34M | $34M | · | $35M | $37M | $37M | · | · | |
| Other Non-current Assets | $59M | $74M | $60M | $20M | $22M | $15M | $52M | $62M | $58M | $51M | · | $43M | $36M | $25M | · | $10M | |
| Total Assets | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Accounts Payable | $808M | $773M | $674M | $584M | $490M | $475M | $462M | $393M | $358M | $417M | · | $503M | $392M | $356M | · | $298M | |
| Current Liabilities | $874M | $832M | $743M | $638M | $546M | $523M | $508M | $430M | $398M | $713M | · | $692M | $582M | $374M | · | $485M | |
| Capital Leases | $402M | $406M | $415M | $428M | $439M | $448M | $455M | $251M | $256M | $253M | · | $86M | $89M | $90M | · | $97M | |
| Deferred Tax | $92M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $298M | $261M | $220M | $196M | $210M | $182M | $166M | $135M | $141M | $120M | · | $69M | $88M | $41M | · | $17M | |
| Total Liabilities | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816M | $796M | $1.09B | · | $846M | $760M | $675M | · | $599M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Retained Earnings | $724M | $590M | $448M | $294M | $84M | $-5M | $29M | $81M | $-49M | $-114M | · | $-305M | $-388M | $-483M | · | $-496M | |
| AOCI | $5M | $400.0K | $13M | $13M | $12M | $9M | $6M | $14M | $2M | $3M | · | $-2M | $-1M | $-3M | · | $-14M | |
| Stockholders' Equity | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | |
| Liabilities + Equity | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Shares Outstanding | 101,600,000 | 100,600,000 | 100,100,000 | 99,700,000 | 99,000,000 | 99,000,000 | 99,400,000 | 101,200,000 | 100,900,000 | 100,600,000 | · | 98,200,000 | 97,600,000 | 97,500,000 | · | 96,100,000 |
Cashflow 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $65M | $57M | $59M | $54M | $53M | $53M | $66M | $42M | $43M | $44M | $38M | $48M | $68M | $40M | $44M | $43M | |
| Amort. of Intangibles | $16M | $100.0K | $1M | $1M | $1M | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $800.0K | $900.0K | $900.0K | $900.0K | $500.0K | $0 | |
| Operating Cash Flow | $136M | $146M | $388M | $228M | $102M | $65M | $242M | $158M | $65M | $130M | $124M | $212M | $180M | $-125M | $143M | $99M | |
| CapEx | $8M | $9M | $-2M | $13M | $12M | $11M | $7M | $8M | $12M | $11M | $5M | $8M | $7M | $8M | $2M | $-2M | |
| Investing Cash Flow | $-135M | $-506M | $-53M | $-197M | $-29M | $14M | $-68M | $25M | $-28M | $-55M | $-202M | $-97M | $-126M | $-42M | $-116M | $-61M | |
| Stock Issued | $85M | $24M | $37M | $46M | $14M | $32M | $10M | $26M | $16M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Stock Repurchased | $12M | $54M | $0 | $0 | $18M | $150M | $300M | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | · | $-30M | · | · | · | $-118M | · | · | · | $70M | · | · | · | $8M | · | · | |
| Financing Cash Flow | $63M | $-86M | $37M | $46M | $-3M | $-118M | $-290M | $26M | $-293M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Net Change in Cash | $64M | $-446M | $373M | $76M | $70M | $-39M | $-116M | $209M | $-257M | $145M | $-43M | $134M | $57M | $-159M | $51M | $49M | |
| Free Cash Flow | · | $137M | · | · | · | $54M | · | · | · | $119M | · | · | · | $-134M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $118M | · | · | · | $-135M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| Net Margin | 15.1% | 24.3% | · | 26.4% | 15.6% | 1.4% | · | 20.9% | 11.0% | 8.4% | · | 16.7% | 21.1% | -18.2% | · | 17.7% | |
| Pretax Margin | 16.9% | 30.3% | · | 36.7% | 23.2% | 2.6% | · | 30.6% | 16.7% | 6.7% | · | 23.2% | 26.9% | -24.6% | · | 25.2% | |
| EBITDA Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| ROA | 3.1% | 4.6% | · | 5.4% | 3.0% | 0.22% | · | 4.1% | 2.2% | 1.5% | · | 3.3% | 4.1% | -3.4% | · | 3.3% | |
| ROE | 4.5% | 6.7% | · | 7.3% | 4.1% | 0.32% | · | 5.5% | 3.0% | 2.1% | · | 4.7% | 5.8% | -5.0% | · | 4.7% | |
| ROIC | 3.6% | 4.5% | · | 5.7% | 3.6% | 0.50% | · | 4.6% | 3.8% | 5.2% | · | 5.1% | 3.1% | -5.0% | · | 4.0% |
Liquidität & Solvenz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.9 | · | 3.4 | 3.2 | 3.1 | · | 4.4 | 4.2 | 2.5 | · | 2.4 | 2.6 | 3.8 | · | 2.5 | |
| Quick Ratio | 1.4 | 1.2 | · | 1.7 | 1.6 | 1.4 | · | 1.9 | 1.5 | 1.2 | · | 1.0 | 0.9 | 1.3 | · | 1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 90.3 | · | 128.4 | 56.6 | -103.8 | · | 73.2 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.2 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.7 |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.26B | $2.87B | · | $2.68B | $2.47B | $2.30B | · | $2.23B | $2.06B | $1.89B | · | $1.76B | $1.64B | $1.50B | · | $1.37B | |
| Net Income TTM | $659M | $523M | · | $455M | $310M | $246M | · | $321M | $287M | $145M | · | $170M | $70M | $-11M | · | $88M | |
| Market Cap | $17.12B | $13.25B | · | $14.00B | $12.44B | $10.95B | · | $11.66B | $13.89B | $13.87B | · | $11.05B | $9.20B | $9.87B | · | $10.21B | |
| P/E | 26.3 | 25.9 | · | 31.8 | 41.8 | 46.7 | · | 37.0 | 48.8 | 98.5 | · | 67.4 | 140.7 | -723.0 | · | 120.7 | |
| P/S | 5.3 | 4.6 | · | 5.2 | 5.0 | 4.8 | · | 5.2 | 6.8 | 7.4 | · | 6.3 | 5.6 | 6.6 | · | 7.4 | |
| P/B | 4.6 | 3.9 | · | 4.7 | 4.6 | 4.3 | · | 4.3 | 5.5 | 5.8 | · | 5.5 | 5.0 | 5.9 | · | 6.6 | |
| P / Tangible Book | 17.7 | 3.9 | · | 4.7 | 4.7 | 4.4 | · | 4.4 | 5.6 | 5.9 | · | 5.6 | 5.1 | 6.0 | · | 6.6 | |
| P / Cash Flow | · | 90.9 | · | · | · | 169.0 | · | · | · | 106.5 | · | · | · | -78.8 | · | · | |
| P / FCF | · | 96.9 | · | · | · | 202.4 | · | · | · | 116.5 | · | · | · | -73.8 | · | · | |
| Earnings Yield | 3.8% | 3.9% | · | 3.1% | 2.4% | 2.1% | · | 2.7% | 2.1% | 1.0% | · | 1.5% | 0.71% | -0.14% | · | 0.83% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Betriebsgewinnmarge % | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| Nettoergebnis | $479M | $341M | $250M | $154M | $90M |
| Verwässerte EPS | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $749M | $557M | $362M | $323M | $233M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
- Optionen für Dezember 2027 jetzt verfügbar für Neurocrine Biosciences (NBIX)
- Aktienmarkt heute, 6. April: Soleno Therapeutics steigt nach Kaufvereinbarung in Höhe von 2,9 Milliarden US-Dollar in bar
- Neurocrine übernimmt Soleno für 2,9 Mrd. US-Dollar in bar; Soleno-Aktie steigt im vorbörslichen Handel
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 827 Einreicher · $10.1B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 153 (+61 vs. Vorquartal) | 62 (-37 vs. Vorquartal) | 300 (+11 vs. Vorquartal) | 223 (+8 vs. Vorquartal) | +9.4M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Dodge & Cox | $941.218.594 | 5.584.707 | 9,32% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $838.307.078 | 4.974.083 | 8,30% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $766.048.708 | 4.545.339 | 7,59% | Aktien |
| STATE STREET CORP | $739.126.759 | 4.385.598 | 7,32% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $393.680.402 | 2.335.897 | 3,90% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $349.922.479 | 2.076.260 | 3,47% | Aktien |
| Vestal Point Capital, LP | $316.845.800 | 1.880.000 | 3,14% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $294.151.210 | 1.750.392 | 2,91% | Aktien |
| RTW INVESTMENTS, LP | $213.689.740 | 1.267.925 | 2,12% | Aktien |
| NORGES BANK | $164.132.866 | 973.880 | 1,63% | Aktien |
| FIRST TRUST ADVISORS LP | $155.578.851 | 923.125 | 1,54% | Aktien |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $122.375.286 | 726.112 | 1,21% | Aktien |
| TWO SIGMA ADVISERS, LP | $119.504.823 | 842.592 | 1,18% | Aktien |
| Swedbank AB | $109.730.107 | 651.082 | 1,09% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $109.170.737 | 647.763 | 1,08% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $109.070.816 | 647.171 | 1,08% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $104.238.729 | 618.499 | 1,03% | Aktien |
| Caisse de depot et placement du Quebec | $91.002.327 | 539.961 | 0,90% | Aktien |
| ARMISTICE CAPITAL, LLC | $90.307.457 | 535.838 | 0,89% | Aktien |
| PRIMECAP MANAGEMENT CO/CA/ | $82.807.988 | 491.340 | 0,82% | Aktien |
| AMERIPRISE FINANCIAL INC | $79.666.260 | 472.708 | 0,79% | Aktien |
| Hood River Capital Management LLC | $79.082.184 | 469.233 | 0,78% | Aktien |
| ROYAL BANK OF CANADA | $73.348.000 | 435.207 | 0,73% | Aktien |
| Pictet Asset Management Holding SA | $72.751.030 | 430.635 | 0,72% | Aktien |
| Gotham Asset Management, LLC | $62.622.213 | 371.568 | 0,62% | Aktien |
| Fiera Capital Corp | $61.558.083 | 365.254 | 0,61% | Aktien |
| BlackRock, Inc. | $61.129.161 | 362.709 | 0,61% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $60.767.710 | 461.270 | 0,60% | Aktien |
| Vinva Investment Management Ltd | $58.838.530 | 346.109 | 0,58% | Aktien |
| AustralianSuper Pty Ltd | $58.817.535 | 348.993 | 0,58% | Aktien |
| GOLDMAN SACHS GROUP INC | $58.206.259 | 345.366 | 0,58% | Aktien |
| BRAIDWELL LP | $56.656.579 | 336.171 | 0,56% | Aktien |
| RHUMBLINE ADVISERS | $52.723.054 | 312.832 | 0,52% | Aktien |
| Clearbridge Investments, LLC | $47.391.031 | 281.194 | 0,47% | Aktien |
| SEIZERT CAPITAL PARTNERS, LLC | $46.740.991 | 277.337 | 0,46% | Aktien |
| Swiss National Bank | $45.319.062 | 268.900 | 0,45% | Aktien |
| BARCLAYS PLC | $44.228.304 | 262.428 | 0,44% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $44.187.600 | 262.192 | 0,44% | Aktien |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $44.038.027 | 261.299 | 0,44% | Aktien |
| Candriam S.C.A. | $43.932.854 | 260.926 | 0,44% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $43.921.064 | 260.605 | 0,43% | Aktien |
| FMR LLC | $40.551.501 | 240.612 | 0,40% | Aktien |
| PRINCIPAL FINANCIAL GROUP INC | $40.285.595 | 239.034 | 0,40% | Aktien |
| California Public Employees Retirement System | $39.090.345 | 231.942 | 0,39% | Aktien |
| RENAISSANCE GROUP LLC | $38.589.515 | 228.970 | 0,38% | Aktien |
| Assenagon Asset Management S.A. | $37.516.902 | 222.606 | 0,37% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $37.508.000 | 222.554 | 0,37% | Aktien |
| Sumitomo Mitsui Trust Group, Inc. | $36.317.270 | 215.488 | 0,36% | Aktien |
| Carmignac Gestion | $36.083.344 | 214.100 | 0,36% | Aktien |
| PFM Health Sciences, LP | $35.966.549 | 213.407 | 0,36% | Aktien |
| Bridgewater Associates, LP | $34.663.773 | 205.677 | 0,34% | Aktien |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $34.304.966 | 203.548 | 0,34% | Aktien |
| Nantahala Capital Management, LLC | $33.707.000 | 200.000 | 0,33% | Kaufoption |
| BANK OF AMERICA CORP /DE/ | $32.143.164 | 190.721 | 0,32% | Aktien |
| MORGAN STANLEY | $32.058.612 | 190.219 | 0,32% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31.213.608 | 185.200 | 0,31% | Verkaufsoption |
| FULLER & THALER ASSET MANAGEMENT, INC. | $30.192.001 | 179.149 | 0,30% | Aktien |
| PRUDENTIAL FINANCIAL INC | $29.909.064 | 177.465 | 0,30% | Aktien |
| SEB Asset Management AB | $29.789.208 | 176.754 | 0,30% | Aktien |
| Ensign Peak Advisors, Inc | $29.653.059 | 175.946 | 0,29% | Aktien |
| IEQ CAPITAL, LLC | $29.628.432 | 175.800 | 0,29% | Aktien |
| MACKENZIE FINANCIAL CORP | $29.609.071 | 175.685 | 0,29% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $29.573.511 | 175.474 | 0,29% | Aktien |
| Korea Investment CORP | $29.154.701 | 172.989 | 0,29% | Aktien |
| PKO BP BANKOWY Universal Pension Society JSC | $28.786.115 | 170.802 | 0,29% | Aktien |
| Zurich Insurance Group Ltd/FI | $28.618.254 | 169.806 | 0,28% | Aktien |
| Impax Asset Management Group plc | $26.965.600 | 160.000 | 0,27% | Aktien |
| Nearwater Capital Markets, Ltd | $26.122.925 | 155.000 | 0,26% | Aktien |
| Mariner, LLC | $25.627.342 | 152.055 | 0,25% | Aktien |
| Integral Health Asset Management, LLC | $25.281.000 | 150.000 | 0,25% | Aktien |
| Rock Springs Capital Management LP | $24.395.441 | 144.750 | 0,24% | Aktien |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $23.738.829 | 140.854 | 0,24% | Aktien |
| Fisher Asset Management, LLC | $22.769.751 | 135.104 | 0,23% | Aktien |
| Aware Super Pty Ltd as trustee of Aware Super | $22.056.175 | 130.870 | 0,22% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $22.009.323 | 130.592 | 0,22% | Aktien |
| Hudson Bay Capital Management LP | $21.909.550 | 130.000 | 0,22% | Aktien |
| Life Cycle Investment Partners Ltd | $21.287.319 | 126.308 | 0,21% | Aktien |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $20.937.370 | 147.623 | 0,21% | Aktien |
| DNB Asset Management AS | $20.280.996 | 120.337 | 0,20% | Aktien |
| JANE STREET GROUP, LLC | $20.072.518 | 119.100 | 0,20% | Verkaufsoption |
| Sarissa Capital Management LP | $19.639.889 | 116.533 | 0,19% | Aktien |
| Andra AP-fonden | $19.522.682 | 148.191 | 0,19% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $19.061.140 | 113.099 | 0,19% | Aktien |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $18.885.863 | 112.059 | 0,19% | Aktien |
| Man Group plc | $18.859.404 | 111.902 | 0,19% | Aktien |
| Mitsubishi UFJ Asset Management Co., Ltd. | $18.788.956 | 111.484 | 0,19% | Aktien |
| UBS Group AG | $18.243.577 | 108.248 | 0,18% | Aktien |
| Robeco Institutional Asset Management B.V. | $18.197.736 | 107.976 | 0,18% | Aktien |
| LOOMIS SAYLES & CO L P | $18.108.412 | 107.446 | 0,18% | Aktien |
| Retirement Systems of Alabama | $17.527.134 | 103.997 | 0,17% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $17.474.389 | 132.643 | 0,17% | Aktien |
| ING GROEP NV | $17.224.277 | 102.200 | 0,17% | Aktien |
| Legal & General Group Plc | $17.176.748 | 101.918 | 0,17% | Aktien |
| RICE HALL JAMES & ASSOCIATES, LLC | $16.886.364 | 100.195 | 0,17% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $16.827.572 | 99.912 | 0,17% | Aktien |
| CWM, LLC | $16.696.728 | 126.740 | 0,17% | Aktien |
| CAPITAL FUND MANAGEMENT S.A. | $16.536.148 | 98.117 | 0,16% | Aktien |
| Clark Capital Management Group, Inc. | $15.629.612 | 92.738 | 0,15% | Aktien |
| Distillate Capital Partners LLC | $15.604.993 | 92.592 | 0,15% | Aktien |
| LAZARD ASSET MANAGEMENT LLC | $15.399.211 | 91.371 | 0,15% | Aktien |
Unternehmensinsider 42 Insider · 21 Führungskräfte · 15 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer | 13. Februar 2025 M | 139.907 | 0 | 0 | $0 |
| Matt Abernethy | Chief Financial Officer | 13. Februar 2025 M | 35.810 | 0 | 0 | $0 |
| Timothy Coughlin | Chief Financial Officer | 6. Februar 2017 S | 137.961 | 0 | 0 | $0 |
| David-Alexandre C Gros | President & COO | 6. Februar 2017 A | — | 0 | 0 | $0 |
| Ingrid Delaet | Chief Regulatory Officer | 10. Juli 2026 M | 16.225 | 0 | 5 | $-3.747.962 |
| Darin Lippoldt | Chief Legal Officer | 9. Juli 2026 M | 54.729 | 0 | 4 | $-3.497.443 |
| Sanjay Chandru Keswani | Chief Medical Officer | 2. Juni 2026 F | 1.479 | 0 | 0 | $0 |
| Julie Cooke | Chief Human Resources Officer | 2. Juni 2026 M | 22.374 | 0 | 1 | $-2.200.685 |
| David W. Boyer | Chief Corp. Affairs Officer | 13. Februar 2025 M | 3.565 | 0 | 0 | $0 |
| Eiry Roberts | Chief Medical Officer | 13. Februar 2025 M | 35.640 | 0 | 0 | $0 |
| Eric Benevich | Chief Commercial Officer | 13. Februar 2025 M | 44.689 | 0 | 0 | $0 |
| Malcolm Lloyd-Smith | Chief Integration Officer | 8. Februar 2023 S | 42.337 | 0 | 0 | $0 |
| Dimitri E. Grigoriadis | Chief Research Officer | 31. Januar 2022 A | 82.273 | 0 | 0 | $0 |
| Haig P. Bozigian | Chief Development Officer | 8. Februar 2021 A | 157.651 | 0 | 0 | $0 |
| Christopher Flint Obrien | Former Chief Medical Officer | 5. Februar 2018 A | 55.946 | 0 | 0 | $0 |
| VALEUR JENSEN MARGARET E | EVP and General Counsel | 31. August 2011 A | 118.256 | 0 | 0 | $0 |
| Richard J Ranieri | Sr. VP, Human Resources | 27. Februar 2008 A | 9.667 | 0 | 0 | $0 |
| Wendall Wierenga | EVP, Research & Development | 19. Januar 2006 A | 5.023 | 0 | 0 | $0 |
| Henry Pan | Executive VP and CMO | 3. Juni 2005 A | 11.216 | 0 | 0 | $0 |
| Robert J Little | SVP, Commercial Operations | 18. Februar 2005 A | — | 0 | 0 | $0 |
| SAUNDERS JOHN | Vice President Research (Chem) | 18. Dezember 2003 S | 7.966 | 0 | 0 | $0 |
| Leslie V Norwalk | Direktor | 29. Juli 2026 M | 2.430 | 0 | 2 | $-437.584 |
| SHERWIN STEPHEN A | Direktor | 5. Juni 2026 M | 15.860 | 0 | 5 | $-4.132.990 |
| William H Rastetter | Direktor | 27. Mai 2026 A | 43.678 | 0 | 1 | $-2.732.760 |
| Kevin Charles Gorman | Direktor | 27. Mai 2026 A | 511.293 | 0 | 1 | $-37.824.431 |
| Christine A Poon | Direktor | 27. Mai 2026 A | 4.753 | 0 | 0 | $0 |
| POPS RICHARD F | Direktor | 27. Mai 2026 A | 37.798 | 0 | 1 | $-2.364.750 |
| LYONS GARY A | Direktor | 27. Mai 2026 A | 122.141 | 0 | 1 | $-2.289.150 |
| MORROW GEORGE J | Direktor | 27. Mai 2026 A | 10.386 | 0 | 1 | $-2.150.550 |
| Johanna Mercier | Direktor | 22. Mai 2025 M | 3.535 | 0 | 0 | $0 |
| Alfred Sandrock | Direktor | 22. Mai 2019 A | — | 0 | 0 | $0 |
| Corinne H Nevinny | Direktor | 24. Mai 2018 A | 43.283 | 0 | 0 | $0 |
| Thomas W Mitchell | Direktor | 28. Mai 2015 A | 1.000 | 0 | 0 | $0 |
| VALE WYLIE W | Direktor | 25. Mai 2011 A | 231.372 | 0 | 0 | $0 |
| Adrian Adams | Direktor | 30. Juni 2006 A | — | 0 | 0 | $0 |
| NEUROCRINE BIOSCIENCES INC | 10%-Eigentümer | 23. Februar 2023 P | 8.575.316 | 0 | 0 | $0 |
| Jude Onyia | — | 4. August 2026 G | 20.996 | 0 | 1 | $-1.762.710 |
| Shalini Sharp | — | 27. Mai 2026 A | 4.088 | 0 | 0 | $0 |
| MOLLICA JOSEPH A | — | 22. Mai 2017 A | 56.042 | 0 | 0 | $0 |
| HAWRAN PAUL W | — | 18. September 2006 J | 132.000 | 0 | 0 | $0 |
| Lawrence Steinman | — | 2. März 2005 S | 15.500 | 0 | 0 | $0 |
| CONLON PAUL J | — | 16. Dezember 2003 S | 57.335 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. ×3 Einreichungen | 24. Februar 2023 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 129 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,71% | 1.793 SH | 8. August 2026 | Täglich |
| PBE · Invesco Exchange-Traded Fund Trust | 2,51% | 55.704 SH | 8. August 2026 | Täglich |
| MCOW · Pacer Funds Trust | 2,17% | 162 NS | 30. April 2026 | N-PORT |
| FGSI · First Trust Exchange-Traded Fund IV | 2,01% | 457 NS | 30. April 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 1,97% | 22.094 SH | 8. August 2026 | Täglich |
| SMRI · EA Series Trust | 1,95% | 79.947 NS | 30. April 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,78% | 55.458 SH | 8. August 2026 | Täglich |
| XMHQ · Invesco Exchange-Traded Fund Trust | 1,74% | 599.955 SH | 8. August 2026 | Täglich |
| BUL · Pacer Funds Trust | 1,66% | 16.032 NS | 30. April 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,38% | 6.192 NS | 30. April 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 1,29% | 23.318 NS | 31. Mai 2026 | N-PORT |
| IBB · iShares Trust | 1,22% | 725.434 SH | 8. August 2026 | Täglich |
| RFG · Invesco Exchange-Traded Fund Trust | 1,16% | 25.502 SH | 8. August 2026 | Täglich |
| AGNG · Global X Funds | 1,12% | 5.792 NS | 31. Mai 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,12% | 5.472 SH | 8. August 2026 | Täglich |
| LABU · Direxion Shares ETF Trust | 0,95% | 37.476 NS | 30. April 2026 | N-PORT |
| AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 0,93% | 7.516 NS | 30. April 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,89% | 99.214 SH | 8. August 2026 | Täglich |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,87% | 57.454 NS | 30. April 2026 | N-PORT |
| IJK · iShares Trust | 0,86% | 588.275 SH | 8. August 2026 | Täglich |
| COWG · Pacer Funds Trust | 0,81% | 132.963 NS | 30. April 2026 | N-PORT |
| BIB · ProShares Trust | 0,80% | 3.712 NS | 31. Mai 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 0,79% | 57.321 SH | 8. August 2026 | Täglich |
| TMFX · RBB Fund, Inc. | 0,76% | 1.542 NS | 31. Mai 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 0,72% | 240 NS | 30. April 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,66% | 25.529 NS | 31. Mai 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,64% | 136 NS | 29. Mai 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,63% | 533 NS | 30. April 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,55% | 13.166 NS | 30. April 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,55% | 5.215 NS | 30. April 2026 | N-PORT |
| XJH · iShares Trust | 0,51% | 13.589 SH | 8. August 2026 | Täglich |
| ISCG · iShares Trust | 0,50% | 31.557 SH | 8. August 2026 | Täglich |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,49% | 13.131 SH | 8. August 2026 | Täglich |
| VBK · VANGUARD INDEX FUNDS | 0,46% | 1.331.820 SH | 8. August 2026 | Täglich |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,46% | 162.408 SH | 8. August 2026 | Täglich |
| QLV · FlexShares Trust | 0,46% | 5.915 NS | 30. April 2026 | N-PORT |
| IJH · iShares Trust | 0,44% | 3.469.295 SH | 8. August 2026 | Täglich |
| SDG · iShares Trust | 0,42% | 4.563 SH | 8. August 2026 | Täglich |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,40% | 15.614 NS | 30. April 2026 | N-PORT |
| IWP · iShares Trust | 0,39% | 493.090 SH | 8. August 2026 | Täglich |
| PTMC · Pacer Funds Trust | 0,39% | 11.519 NS | 30. April 2026 | N-PORT |
| USMV · iShares Trust | 0,35% | 534.448 SH | 8. August 2026 | Täglich |
| MVV · ProShares Trust | 0,34% | 3.468 NS | 31. Mai 2026 | N-PORT |
| SXQG · EXCHANGE TRADED CONCEPTS TRUST | 0,34% | 1.461 NS | 31. Mai 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,34% | 16.076 NS | 30. April 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,29% | 271.303 NS | 31. Mai 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,26% | 1.662 NS | 30. April 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,26% | 40.014 NS | 30. April 2026 | N-PORT |
| IYH · iShares Trust | 0,26% | 59.243 SH | 8. August 2026 | Täglich |
| ISCB · iShares Trust | 0,25% | 4.488 SH | 8. August 2026 | Täglich |